Practice parameter: Immunotherapy for Guillain-Barré syndrome - Report of the Quality Standards Subcommittee of the American Academy of Neurology

Neurology

Volumn 61, Issue 6, 2003, Pages 736-740

  Hughes, R A C ^a   Wijdicks, E F M ^b   Barohn, R ^c   Benson, E ^d   Cornblath, D R ^f   Hahn, A F ^e   Meythaler, J M ^g   Miller, R G ^h   Sladky, J T ⁱ   Stevens, J C ^j  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d Guillain Barre Syndrome Found Intl   (United States)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Fort Wayne Neurological Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE; STEROID;

AMBULATORY CARE; ARTIFICIAL VENTILATION; ATELECTASIS; BLOOD CLOTTING DISORDER; CHILD CARE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG CONTRAINDICATION; ERYTHEMA; EVIDENCE BASED MEDICINE; GUILLAIN BARRE SYNDROME; HEART INFARCTION; HEMODYNAMICS; HUMAN; HYPOCALCEMIA; HYPOTENSION; IMMUNOADSORPTION; IMMUNOTHERAPY; KIDNEY FAILURE; MALAISE; MEDICAL DECISION MAKING; MENINGISM; NEUROPATHY; PLASMAPHERESIS; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPTICEMIA; STEROID THERAPY; THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING; WALKING;

EID: 10744231704     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.61.6.736     Document Type: Review

References (46)

1. Hughes RAC, Rees JH. Clinical and epidemiological features of Guillain-Barré syndrome. J Infect Dis 1997;176(suppl 2):S92-S98.
2. Van Koningsveld R, van Doorn PA, Schmitz PI, et al. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in The Netherlands. Neurology 2000;54:620-625.
3. Prevots DR, Sutter RW. Assessment of Guillain-Barre syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis 1997;175(suppl 1):S151-S155.
4. Raphael JC, Masson C, Morice V, et al. Le syndrome de Guillain-Barré: étude retrospective de 233 observations. Sem Hop Paris 1984;60:2543-2546.
5. Rees JH, Thompson RD, Smeeton NC, Hughes RAC. An epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry 1998;64:74-77.
6. The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. Brain 1996;119:2053-2061.
7. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-230.
8. Merkies IS, Schmitz PI, Samijn JP, et al. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999;53:1648-1654.
9. Buzby JC, Allos B, Roberts T. Annual costs of Guillain-Barré syndrome in the United States. Ann Neurol 1995;38:348.
10. Buzby JC, Roberts T, Allos B. Estimated annual costs of Campylobacter-associated Guillain-Barré syndrome. Agricultural Economic Report No. 756. Washington, DC: United States Department of Agriculture, 1997.
11. Asbury AK, Arnason BGW, Karp HR, McFarlin DF. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1978;3:565-566.
12. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;(27 suppl):S21-S24.
13. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.
14. Raphael J-C, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome (Cochrane review). Cochrane Database of Systematic Reviews 2. Oxford: Update Software, 2001.
15. French Cooperative Group in Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987;22:753-761.
16. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992;32:94-97.
17. Greenwood RJ, Newsom Davis JM, Hughes RAC, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;1:877-879.
18. Osterman PO, Lundemo G, Pirskanen R, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;2:1296-1299.
19. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-1104.
20. Farkkila M, Kinnlinen E, Haapanen E, Inanainen M. Guillain-Barré syndrome: quantitative measurement of plasma exchange therapy. Neurology 1987;37:837-840.
21. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997;41:298-306.
22. Tharakan J, Ferner RE, Hughes RAC, et al. Plasma exchange for Guillain-Barré syndrome. J R Soc Med 1989;82:458-461.
23. Espérou H, Jars Guincestre MC, Bolgert F, et al. Cost-effectiveness of plasma exchange therapy for the treatment of Guillain-Barré syndrome. Intensive Care Med 2000;26:1094-1100.
24. Wollinsky KH, Hulser PJ, Brinkmeier H, et al. CSF filtration is an effective treatment of Guillain-Barre syndrome: a randomized clinical trial. Neurology 2001;57:774-780
25. Feasby TE, Hartung HP. Drain the roots: a new treatment for Guillain-Barre syndrome? Neurology 2001;57:753-754.
26. Haupt WF, Rosenow F, van der Ven C, et al. Sequential treatment of Guillain-Barre syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci 1996;137:145-149.
27. Hughes RAC, Raphael J-C, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome (Cochrane review). Cochrane Database of Systematic Reviews 3. Oxford: Update Software, 2001.
28. Gürses N, Uysal S, Cetinkaya F, et al. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995;27:241-243.
29. van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
30. Bril V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996;46:100-103.
31. Hughes RAC, van der Meché FGA, Corticosteroid treatment for Guillain-Barré syndrome (Cochrane review). Cochrane Database of Systematic Reviews 4. Oxford: Update Software, 1999.
32. Swick HM, McQuillen MP. The use of steroids in the treatment of idiopathic polyneuritis. Neurology 1976;26:205-212.
33. , Mendell JR, Kissel JT, Kennedy MS, et al. Plasma exchange and prednisone in Guillain-Barre syndrome. A controlled randomized trial. Neurology 1985;35:1551-1555.
34. Shukla SK, Agarwal R, Gupta OP, Pande G, Mamta S. Double blind control trial of prednisolone in Guillain-Barré syndrome: a clinical study. Clin India 1988;52:128-134.
35. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341:586-590.
36. Singh NK, Gupta A. Do corticosteroids influence the disease course or mortality in Guillain-Barré syndrome. J Assoc Physicians India 1996;44:22-24.
37. The Dutch Guillain-Barré Study Group. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994;35:749-752.
38. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-342.
39. Nguyen DK, Agenarioti-Belanger S, Vanasse M. Pain and the Guillain-Barre syndrome in children under 6 years old, J Pediatr 1999;134:773-776.
40. McKhann GM, Cornblath DR, Ho TW, Li CY, Bai AY, Wu HS. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991;338:593-597.
41. Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain-Barre syndrome. Ann Neurol 1990;28:65-69.
42. Khatri BO, Flamini JR, Baruah JK, Dobyns WB, Konkol RJ. Plasmapheresis with acute inflammatory polyneuropathy. Pediatr Neurol 1990;6:17-19.
43. Lamont PJ, Johnston HM, Berdoukas VA. Plasmapheresis in children with Guillain-Barré syndrome. Neurology 1991;41:1928-1931.
44. Jansen PW, Perkin RM, Ashwal S. Guillain-Barré syndrome in childhood: natural course and efficacy of plasmapheresis. Pediatr Neurol 1993;9:16-20.
45. Shahar E, Murphy EG, Roifman CM. Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome. J Pediatr 1990;116:141-144.
46. Abd-Allah SA, Jansen PW, Ashwal S, Perkin RM. Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome. J Child Neurol 1997;12:376-380.